The complete response (CR) rate to the combination of the interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva®) and bacillus Calmette-Guerin (BCG) in BCG-unresponsive nonmuscle ...
TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...
People with overactive bladder (OAB) experience a strong and sudden urge to urinate. They may find themselves waking up two or more times each night to use the bathroom. OAB may also cause involuntary ...
The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results